Issued 2026-09-25 at $8.01 · now $8.01 (2026-09-25, +0.0% since)
Based on its own history, a month from the 2026-09-25 close, EPRX has typically landed between $6.81 and $10.84 — a range of −15.0% to +35.3% from the issuance price $8.01.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
600 overlapping 1 month windows · 2024-04-05 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.
The cone is anchored at the 2026-09-25 issuance close ($8.01) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where EPRX has typically landed a month from the 2026-09-25 close of $8.01 — the range is history, not a prediction.
- now $8.01 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $8.1 (+1.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $7.39–$8.81
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $6.81–$10.84
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-03-10 | −27.9% | −28.9% | +1.9% |
| 2025-03-07 | −27.9% | −29.6% | +1.0% |
| 2025-03-12 | −27.9% | −30.2% | +0.0% |
| 3 best | |||
| 2025-05-30 | +50.5% | −0.5% | +50.5% |
| 2024-10-22 | +49.4% | +0.0% | +49.4% |
| 2025-05-29 | +46.6% | −1.8% | +46.6% |
600 overlapping windows · 2024-04-05 – 2026-09-25 · not cherry-picked
Pending catalysts
- December 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~3 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
No Form 4 filings for this company are in our record yet.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.